Nkarta, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Nkarta, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-09-30 was 208.00 shares.
- Nkarta, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-06-30 was 14.38K shares.
- Nkarta, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2024-03-31 was 128.67K shares.
- Nkarta, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-09-30 was 265.99K shares, a 320.70% increase year-over-year.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2024-09-30 | 208.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | |
| 2024-06-30 | 14.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | |
| 2024-03-31 | 128.67K shares 10-Q · filed 2024-05-09 | |
| 2022-09-30 | 265.99K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2022-06-30 | 88.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | |
| 2022-03-31 | 21.07K shares 10-Q · filed 2022-05-12 | |
| 2021-09-30 | 63.23K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | |
| 2021-06-30 | 39.03K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 155.32K shares 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |